Table 3 Socio-demographic characteristics, Laboratory investigations and Ultrasound finding among patients of the studied groups.

From: Correction: The interaction between microRNA-152 and DNA methyltransferase-1 as an epigenetic prognostic biomarker in HCV-induced liver cirrhosis and HCC patients

  

Control

N = 20

Group I

(CLD without HCC) N = 40

Group II

(CLD with HCC)

N = 20

 
 

Group Ia

(CLD without Cirrhosis)

N = 18

Group Ib

(CLD with Cirrhosis)

N = 22

P-value

Age

47.1 ± 8.5

47.7 ± 9.9

58.9 ± 9.3

56.3 ± 7.8

0.01*

Sex

Female

2 (10.0%)

10 (55.6%)

11 (50.0%)

4 (20.0%)

0.6

Male

18 (90.0%)

8 (44.4%)

11 (50.0%)

16 (80.0%)

U.S Finding

Cirrhosis

0 (0.0%)

0 (0.0%)

22 (100.0%)

6 (30.0%)

0.01*

Splenomegaly

0 (0.0%)

2 (11.11%)

17 (77.3%)

18 (90.0%)

Ascites

0 (0.0%)

0 (0.0%)

18 (82.0%)

20 (100.0%)

ALT

27.5 (15.5–31.8)

40.0 (17.0–51.0)

46.5 (24.3–84.8)

55.5 (34.5–82.5)

0.001**

AST

31.10 ± 6.77

43.63 ± 12.39

66.40 ± 21.44

95.67 ± 38.95

0.001**

AFP

2.3 (1.5–3.1)

2.2 (1.4–4.5)

8.8 (6.5–16.8)

224.0 (44.3–597.5)

0.001**

Albumin

4.1 ± 0.5

4.1 ± 0.5

3.1 ± 1.1

2.6 ± 0.7

0.001**

Total bilirubin

0.9 (0.8–1.1)

0.6 (0.4–0.9)

1.4 (0.7–3.6)

1.9 (1.3–5.0)

0.001**

Direct bilirubin

0.3 (0.2–0.4)

0.2 (0.1–0.3)

0.6 (0.2–1.9)

1.1 (0.4–2.5)

0.001**

ALP.

74.3 ± 19.0

84.9 ± 30.2

103.2 ± 35.6

202.4 ± 88.0

0.001**

PT

12.4 (11.4–12.8)

15.4 (13.2–18.8)

17.8 (15.0–20.4)

16.3 (14.5–19.0)

0.001**

PC

89.6 (78.2–100.0)

64.0 (55.0–80.0)

52.5 (44.0–73.8)

71.5 (55.0–75.3)

0.001**

INR

1.1 (1.0–1.1)

1.5 (1.0–1.6)

1.5 (1.2–1.8)

1.4 (1.2–1.5)

0.001**

HB

12.6 ± 1.4

12.4 ± 1.6

10.4 ± 2.2

11.2 ± 2.4

0.002**

WBCs

6.2 ± 2.3

7.0 ± 2.8

7.3 ± 2.6

7.8 ± 3.1

0.4

Platelets

241.50 ± 56.48

183.58 ± 35.32

97.35 ± 19.42

140.1 ± 69.5

0.001**

APRI score

0.34 ± 0.13

0.61 ± 0.17

1.69 ± 0.31

2.1 ± 1.3

0.001**

  1. Age, AST, albumin, ALK, HB, WBCs, platelets and APRI score are represented as mean ± SD; the data were analyzed by ANOVA test. But sex and U/S finding are represented as frequency and percent; the data were analyzed by X2 test. While ALT, AFP, total bilirubin, direct bilirubin, PT, PC and INR are represented as median and interquartile range (25–75%); the data were analyzed by Kruskal–Wallis test.
  2. APRI score calculated regarding AST to platelet ratio index (APRI) = [AST level (IU/L)/AST (upper limit of normal) (IU/L)]/platelet count (109/L) × 100 (normal <0.05, CLD without cirrhosis 0.5–1.5 and Cirrhosis ≤1.5).
  3. *P value <0.01 is significant.
  4. **P value <0.001 is highly significant.
Back to article page